Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Indian cancer patients battle shortage of key drugs as platinum costs surge
Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues are causing shortages. This forces patients to search extensively for medication. Some drugmakers have reduced production. The situation puts immense pressure on the healthcare system and patients seeking treatment.
Is the global IT stock rout a wake-up call for AI optimists?
Investors are wondering how long it will take for AI-related investments to convert into substantial IT revenue growth and whether large global IT stocks are overvalued.
AI-led global earnings pressure India; opportunities in power, pharma: Conrad Saldanha
Neuberger Berman MD & Portfolio Manager Conrad Saldanha discusses why AI-driven earnings growth in the US, Korea and Taiwan continues to attract capital, shares his outlook on India, and highlights opportunities in power infrastructure, airports, specialty pharma and select financials.
Carlyle-backed Viyash Scientific buys Italy’s BioForLife for Rs 188 crore
Viyash Scientific, backed by Carlyle, is acquiring Italy's BioForLife for Rs. 188 crore. This move aims to build a leading global companion animal health business. BioForLife offers a strong presence in the Italian pet care market. The acquisition is expected to finalize in the second quarter of FY 2026-27.
Lupin partners ERN to launch asthma and COPD treatment in Spain
Lupin has partnered Spain's ERN to launch Luforbec for asthma and COPD, extending its respiratory franchise in Europe as the drugmaker continues to build momentum across key global markets.
Alembic Pharma to acquire 45% stake in Canadian venture for pharma market expansion
Alembic Pharmaceuticals enters a Canadian joint venture with a 45% stake as it looks to strengthen its global pharma footprint. Alembic Pharmaceuticals shares closed at ₹742.75 on the NSE, up ₹5.20 or 0.71%.
Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.
Global companies exploit India's IPO boom to take profits back home
Sky-high Indian valuations are prompting foreign firms to use IPOs for partial exits and profit repatriation, with many preferring cashing out investments over raising fresh capital for expansion
Analysis-Global firms exploit India’s IPO boom to take profits back to home countries By Reuters - Investing.com
Analysis-Global firms exploit India’s IPO boom to take profits back to home countries By ReutersInvesting.com
Global firms exploit India's IPO boom to take profits back to home countries - Reuters
Global firms exploit India's IPO boom to take profits back to home countriesReuters
Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facility
Aurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines for global markets. US pharma giant MSD is the first major client. The plant signifies Aurobindo's expansion into the growing biologics and contract manufacturing sector. It is set to create over 1,500 jobs.
AksharChem (India) Ltd leads gainers in 'B' group
Jeena Sikho Lifecare Ltd, JHS Svendgaard Retail Ventures Ltd, Emkay Global Financial Services Ltd and John Cockerill India Ltd are among the other gainers in the BSE's 'B' group today, 03 June 2026.